Should the Patient Continue Auvelity After Vomiting on Day 2?
The patient should continue Auvelity unless the vomiting is severe, persistent, or accompanied by other concerning symptoms. A single episode of vomiting on day 2 does not automatically warrant discontinuation, as nausea and vomiting are common early side effects that often resolve with continued treatment.
Clinical Reasoning
Nausea/Vomiting as Expected Side Effects
Nausea is among the most common adverse effects reported with Auvelity 1. In clinical trials, nausea was frequently observed but was typically rated as mild-to-moderate in severity 2. The FDA label for Auvelity lists nausea as one of the most common adverse events 3.
More broadly, nausea and vomiting are the most common reasons for discontinuation in antidepressant efficacy studies 4. However, this reflects discontinuation in controlled trials, not necessarily what should occur in real-world practice where side effects often improve with time.
Decision Algorithm for Continuation
Continue Auvelity if:
- Single or infrequent vomiting episodes
- Patient can maintain hydration and nutrition
- No signs of severe adverse reactions (seizures, severe hypertension, altered mental status, serotonin syndrome)
- Vomiting is improving or stable, not worsening
Consider discontinuation if:
- Persistent, intractable vomiting preventing medication absorption
- Dehydration or inability to maintain oral intake
- Vomiting accompanied by concerning neurological symptoms (confusion, seizure activity, severe headache)
- Signs of serotonin syndrome (agitation, hyperthermia, muscle rigidity, autonomic instability) 3
- Patient distress is severe enough to compromise treatment adherence
Management Strategies
Supportive measures to continue treatment:
- Take medication with food to reduce GI upset
- Ensure adequate hydration
- Consider anti-emetic support if needed (ondansetron, metoclopramide)
- Reassure patient that GI side effects often diminish within 1-2 weeks
- Monitor closely over the next 24-48 hours
Critical Safety Monitoring
While managing the vomiting, actively screen for more serious adverse events that would mandate immediate discontinuation 3:
- Seizure activity (bupropion component carries dose-related seizure risk)
- Severe hypertension (monitor blood pressure)
- Serotonin syndrome (especially if patient is on other serotonergic medications)
- Neuropsychiatric symptoms (agitation, hallucinations, confusion, suicidal ideation)
Common Pitfall to Avoid
Do not prematurely discontinue a potentially effective antidepressant for transient GI side effects that are likely to resolve. Depression itself carries significant morbidity and mortality risk. However, balance this against the patient's ability to tolerate the medication and maintain adherence. If the patient is miserable and cannot function due to vomiting, the medication won't help their depression regardless of its efficacy profile.
Context of Auvelity's Benefits
Auvelity has demonstrated rapid onset of antidepressant effects, with significant improvement seen as early as week 1-2 5, 2, 6. Remission rates approached 70% in long-term studies 2. Discontinuing prematurely for manageable side effects means potentially losing access to these benefits in a patient who may have failed other treatments.
Monitor the patient closely over the next 24-48 hours with specific attention to vomiting frequency, hydration status, and emergence of any neurological or psychiatric symptoms. If vomiting remains isolated and mild, continue treatment with supportive care.